Effect of Systemic Retinoic Acid Use on Micro Ribonucleic Acid (mRNA) Expression
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Saliva, serum sampling, oral isotretinoin.
- Who it may be relevant to
- Registry conditions: Periodontal Diseases, Inflammation. Basic parameters: 18 years — 45 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of the Effect of Systemic Retinoic Acid Use on Micro Ribonucleic Acid (mRNA) Expression in Saliva and Serum
Overview
Ribonucleic acids (RNA) are molecules that transfer genetic information from the nucleus to the cytoplasm for protein translation. A subgroup of non-coding or non-messenger RNAs, known as microRNAs (miRNAs), regulates the expression of complementary mRNAs without coding for proteins. In this study, the investigators aimed to evaluate the effect of systemically administered oral isotretinoin on gingival health in terms of microRNA (miRNA), a molecule of interest in periodontal research, before, during, and after treatment.
Detailed description
Healthy participants (n:25) enrolled for this study. Samples will be collected for each patient at the following time points: immediately before the initiation of retinoic acid treatment, during treatment at week 5 (T1), during treatment at month 5 (T2), and three months after the end of treatment (T3).
Interventions
- Other Saliva, serum sampling
Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, serum were then stored at -80 °C until analysis. - Drug oral isotretinoin
oral isotretinoin
Primary outcome measures
- Pocket probing depth [Time frame: 6 months]
- Clinical attachment level [Time frame: 6 months]
- Bleeding on probing [Time frame: 6 months]
Secondary outcome measures (1)
- Saliva, serum samples processing and analyses [Time frame: 1 month]
Eligibility criteria
Inclusion criteria
- systemically healthy
- over 18 and under 45 years of age
- have at least 20 natural permanent teeth in occlusion excluding third molars,
- not be pregnant,
- have not used any antimicrobial and/or anti-inflammatory drugs in the past 3 months,
- have not received periodontal treatment in the past 6 months,
- have not undergone surgical periodontal treatment within the past year.
Exclusion criteria
- history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months)
- nonsurgical periodontal treatment (previous 6 months)
- surgical periodontal treatment (previous 12 months)
- current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy)
- pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Turkey (Türkiye) · 1 center
- Istanbul Medipol University, School of Dentistry — Istanbul
Identifiers
NCT: NCT07142070 · 1386